- Daiichi Sankyo, Inc. (Bernards, NJ)
- …as other research areas centered around rare diseases and immune disorders.Summary The Senior Director sits within Global Oncology Clinical Development, an ... 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology ," Daiichi Sankyo is primarily focused on providing novel therapies in … more
- Eisai, Inc (Nutley, NJ)
- …We're a growing pharmaceutical company that is breaking through in neurology and oncology , with a strong emphasis on research and development. Our history includes ... a difference. If this is your profile, we want to hear from you.The Director , Advanced and Omnichannel Analytics will be a member of the Business Intelligence team… more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …researching on real-world evidence, and creating hope for all facing illness. The Senior Director , Regulatory Affairs - Clinical (Neuroderm), may be called upon ... (SCI), and in high unmet areas in Immunology and Oncology . MTPA is rapidly expanding its operations across all...plans to facilitate timely drug development and registration. The Senior Director , Regulatory Affairs - Clinical also… more
- Axtria, Inc. (Berkeley Heights, NJ)
- …some of the brightest minds in the industry. Description: We are looking for Senior Manager and Associate Director for our Decision Science practice. Success in ... team to deliver Decision Science consulting projects. + Directly work with senior Client and Axtria stakeholders in a highly consultative and responsive manner,… more
- Merck (Rahway, NJ)
- …incumbent may initially work in a specific disease area, such as oncology , including hematology. **Primary activities** **:** + Directs the scientific and technical ... trial designs, and statistical and data processing software eg SAS and/or R . + Solid knowledge of worldwide regulatory requirements and clinical trial expertise… more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …of the project with regards to timeline, resources, and budget. Additionally, the Associate Director will support the Senior Director /Head of the Department, ... (SCI), and in high unmet areas in Immunology and Oncology . MTPA is rapidly expanding its operations across all...filling in for the Senior Director during travel or other leave, and supporting a… more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …programs and in creating and implementing experimental medicine studies. Reporting into the Senior Director of the Medical Science Early-Stage, the Director , ... (SCI), and in high unmet areas in Immunology and Oncology . MTPA is rapidly expanding its operations across all...the United States, MTPA launched rare disease treatments including RADICAVA( R ) (edaravone) injectables in 2017 and RADICAVA( R )… more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …Spinal Cord Injury (SCI), and in high unmet areas in Immunology and Oncology . MTPA is rapidly expanding its operations across all functional areas. MTPA's commitment ... markets. In the United States, MTPA launched rare disease treatments including RADICAVA( R ) (edaravone) injectables in 2017 and RADICAVA( R ) (edaravone) oral… more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …Spinal Cord Injury (SCI), and in high unmet areas in Immunology and Oncology . MTPA is rapidly expanding its operations across all functional areas. MTPA's commitment ... markets. In the United States, MTPA launched rare disease treatments including RADICAVA( R ) (edaravone) injectables in 2017 and RADICAVA( R ) (edaravone) oral… more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …Spinal Cord Injury (SCI), and in high unmet areas in Immunology and Oncology . MTPA is rapidly expanding its operations across all functional areas. MTPA's commitment ... markets. In the United States, MTPA launched rare disease treatments including RADICAVA( R ) (edaravone) injectables in 2017 and RADICAVA( R ) (edaravone) oral… more
- Mitsubishi Chemical Group (Jersey City, NJ)
- …Spinal Cord Injury (SCI), and in high unmet areas in Immunology and Oncology . MTPA is rapidly expanding its operations across all functional areas. MTPA's commitment ... markets. In the United States, MTPA launched rare disease treatments including RADICAVA( R ) (edaravone) injectables in 2017 and RADICAVA( R ) (edaravone) oral… more
